TAK 792Alternative Names: TAK-792
Latest Information Update: 23 May 2015
At a glance
- Originator Takeda
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 01 May 2015 Takeda plans a phase I trial in Healthy volunteers in Japan (NCT02448719)